Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.77 |
| ▸ | F10 | P00742 | 3/20 | 0.77 |
| ▸ | PRMT1 | Q99873 | 6/20 | 0.52 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.47 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.47 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5034730 | 0.87 | F2 (0.81) | F2F10PRMT1TPSAB1TPSD1 | |
| SCHEMBL237460 | 0.87 | F2 (1.00) | F2F10PRMT1TPSAB1TPSD1 | |
| Hydrochloric Acid SCHEMBL5028092 | 0.85 | F2 (0.79) | F2F10PRMT1TPSAB1TPSD1 | |
| Hydrochloric Acid SCHEMBL5028046 | 0.85 | F2 (0.97) | F2F10PRMT1TPSAB1TPSD1 | |
| SCHEMBL5030493 | 0.84 | F2 (0.88) | F2F10PRMT1TPSAB1TPSD1 | |
| SCHEMBL5028071 | 0.84 | F2 (0.88) | F2F10PRMT1 | |
| Hydrochloric Acid SCHEMBL5034833 | 0.83 | F2 (0.85) | F2F10PRMT1 | |
| Hydrochloric Acid SCHEMBL5034703 | 0.83 | F2 (0.85) | F2F10PRMT1 | |
| SCHEMBL5032861 | 0.83 | F2 (0.85) | F2F10PRMT1TPSAB1TPSD1 | |
| SCHEMBL7979967 | 0.83 | F2 (0.85) | F2F10PRMT1TPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999042439-A1 | NOVEL THIOBENZAMIDES | ROCHE DIAGNOSTICS GMBH (DE) | 1999-08-26 | — | — | WO | disclosed |
| WO-1999042462-A1 | SULFONAMIDES WITH ANTITHROMBOTIC ACTIVITY | ROCHE DIAGNOSTICS GMBH (DE) | 1999-08-26 | — | — | WO | disclosed |